Regeneron and sanofi provide update on ongoing dupixent® (dupilumab) chronic spontaneous urticaria phase 3 program

Tarrytown, n.y. and paris, feb. 18, 2022 /prnewswire/ -- in a phase 3 trial in patients refractory to omalizumab, dupixent did not reach statistical significance in interim analysis despite numeric improvements observed across key endpoints; trial will be stopped due to futility positive results from a previous phase 3 trial in biologic-naÏve patients showed dupixent significantly reduced itch and hives compared to standard-of-care antihistamines alone companies remain committed to advancing dupixent for patients with chronic spontaneous urticaria uncontrolled on antihistamines and are evaluating next steps regeneron pharmaceuticals, inc. (nasdaq: regn) and sanofi today announced a phase 3 trial (cupid study b) evaluating dupixent® (dupilumab) in patients with chronic spontaneous urticaria (csu) will stop due to futility, based on a pre-specified interim analysis.
REGN Ratings Summary
REGN Quant Ranking